AG
IBRX icon

Algert Global’s ImmunityBio IBRX Stock Holding History

Algert Global’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$851K Sell
97,160
-86,400
-47% -$654K 0.01% 992
2026
Q1 		$1.41M Buy
+183,560
New +$1.26M 0.02% 790
2024
Q3 		– Sell
-13,560
Closed -$85.7K – 1365
2024
Q2 		$85.7K Buy
+13,560
New +$89.4K ﹤0.01% 1406

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Algert Global's IBRX Position: Q2 2026 in Review

Algert Global reduced its ImmunityBio (IBRX) stake by 47% in Q2 2026, selling an estimated $654K and leaving 97,160 shares worth $851K. The position accounts for 0.01% of the portfolio, ranked #992.

Algert Global first reported a position in IBRX in Q2 2024 and has held it in 3 quarters since. The position peaked at $1.41M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Algert Global held 97,160 shares of ImmunityBio worth $851K as of Q2 2026.
  • Algert Global sold 86,400 ImmunityBio shares in Q2 2026, an estimated $654K.
  • ImmunityBio made up 0.01% of Algert Global's portfolio in Q2 2026, its #992 holding.
  • Algert Global first reported a position in ImmunityBio in Q2 2024 and has held it in 3 quarters since.
  • Algert Global's ImmunityBio position peaked at $1.41M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.